Patient capital, held in equilibrium.

Before there was a Lennard-Jones potential, there was John Edward Jones and Kathleen Lennard. When they married, John took his wife's family name and placed it before his own — an homage to her brothers, who had lost their lives in the First World War. It was a quiet, deliberate act of devotion: two families joined into one name, with hers first.

In 1924, John Edward Lennard-Jones introduced the potential that now carries that name. It describes how two neutral molecules interact: a gentle attraction at a distance and a strong repulsion up close. Between them sits a point of stable equilibrium.

Chemistry is the common thread. From the compounds inside a seed to the molecules that shape how we age, our companies work where chemistry meets biology — using data and AI to understand how molecules interact with living systems, and turning that understanding into real products.

Lennard-Jones Holdings is built on both ideas. Behind the science is a bond of love and commitment, and we want that spirit to live in how we treat our people, our partners, and our work. Our companies stay independent, each with its own team and focus, while drawing on shared capital, governance, and scientific insight — close enough to compound together, never so close that they lose their edge.